[Preclinical models in oncology]

Area of Science:

• Oncology
• Preclinical Research
• Drug Development

Context:

• Cancer research requires diverse tumor models tailored to specific study objectives.
• Tumor model selection is critical across various preclinical development stages, including target validation, lead compound testing, and candidate selection.
• Heterogeneity in cancer necessitates a range of models to accurately reflect disease complexity.

Purpose:

• To outline the strategic selection of tumor models in oncology research based on study objectives.
• To detail the utility of various tumor models, from subcutaneous implants to genetically engineered animals, in preclinical drug development.
• To emphasize the need for advanced models, such as orthotopic grafts and humanized targets, for specific research questions.

Summary:

• Subcutaneous tumor implantation models are commonly used for preclinical questions and clinical development preparation.
• More complex models, including orthotopic grafts and genetically engineered animals, are essential for investigating specific tumor-stroma interactions and mimicking tumor development stages.
• Humanized target models are also employed to better recapitulate human cancer biology in preclinical settings.

Impact:

• Informed tumor model selection accelerates the preclinical phase of oncology drug development.
• Utilizing appropriate models enhances the predictive accuracy of preclinical findings for clinical outcomes.
• Advanced tumor models provide deeper insights into cancer biology and therapeutic responses, facilitating the development of novel cancer treatments.